Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals has 32 drugs tracked on RxWires: 6 in Phase 3, 9 in Phase 2, 3 in Phase 1/2, 14 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Lumasiran | Phase 3 | Primary Hyperoxaluria Type 1 (PH1) |
| patisiran (ALN-TTR02) | Phase 3 | TTR-mediated Amyloidosis |
| Nucresiran | Phase 3 | Transthyretin Amyloidosis With Cardiomyopathy |
| Vutrisiran | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy |
| Revusiran (ALN-TTRSC) | Phase 3 | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) |
| Zilebesiran | Phase 3 | High Risk Cardiovascular Disease |
| VIR-2218 | Phase 2 | Chronic Hepatitis B |
| ALN-RSV01 | Phase 2 | Respiratory Syncytial Virus Infections |
| ALN-AGT01 | Phase 2 | Hypertension |
| Mivelsiran | Phase 2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) |
| ALN-AGT01 RVR | Phase 2 | Hypertension |
| Indapamide | Phase 2 | Hypertension |
| ALN-6400 | Phase 2 | Von Willebrand Disease (VWD) |
| ALN-4324 | Phase 2 | Type 2 Diabetes Mellitus (T2DM) |
| ALN-APP | Phase 2 | Cerebral Amyloid Angiopathy |
| ALN-2232 | Phase 1/2 | Obesity |
| ALN-XDH | Phase 1/2 | Gout |
| ALN-AAT02 | Phase 1/2 | ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease |
| givosiran (ALN-AS1) | Phase 1 | Acute Intermittent Porphyria |
| ALN-5288 | Phase 1 | Alzheimer's Disease |
| ALN-TTRSC04 | Phase 1 | Transthyretin-Mediated Amyloidosis |
| ALN-HSD | Phase 1 | Nonalcoholic Steatohepatitis |
| ALN-HBV | Phase 1 | Hepatitis B |
| ALN-4915 | Phase 1 | Healthy Volunteers |
| ALN-6222 | Phase 1 | Obesity |
| ALN-4285 | Phase 1 | Healthy Volunteers |
| ALN-PCSSC | Phase 1 | Hypercholesterolemia |
| ALN-TTR01 | Phase 1 | Transthyretin Mediated Amyloidosis (ATTR) |
| ALN-PCS02 | Phase 1 | Elevated LDL-Cholesterol (LDL-C) |
| ALN-VSP02 | Phase 1 | Solid Tumors |
| ALN-HTT02 | Phase 1 | Huntington's Disease |
| ALN-BCAT | Phase 1 | Advanced Hepatocellular Carcinoma |
Latest
- Zilebesiran moved to Phase 3
- Aln 6400 moved to Phase 2
- alnylam pharmaceuticals filed 8-K
- alnylam pharmaceuticals filed 8-K
- alnylam pharmaceuticals filed 8-K
Follow Alnylam Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.